Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-13 of 13
Keywords: Sorafenib
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Journal:
Case Reports in Oncology
Case Rep Oncol (2023) 16 (1): 1087–1094.
Published Online: 11 October 2023
... pulmonary edema from rapid fluid remobilization into intravascular compartment. Drug-induced etiology is an important diagnostic consideration in cancer patients, particularly with use of antimetabolites, immunostimulants, and monoclonal antibodies. Sorafenib-mediated capillary leak syndrome has never been...
Journal Articles
Subject Area:
Oncology
Charlotte Brinch, Marie Dehnfeld, Estrid Hogdall, Tim Svenstrup Poulsen, Anders Toxvaerd, Gina Al-Farra, Magnus Bergenfeldt, Anders Krarup-Hansen
Journal:
Case Reports in Oncology
Case Rep Oncol (2022) 14 (3): 1567–1573.
Published Online: 05 November 2021
... shortly after introduction and subsequently progressed on sunitinib and nilotinib. The patient started fourth-line treatment with sorafenib with an impressive response to a point at which metastases intra-abdominally and in the liver could be resected. After surgery, sorafenib was restarted. Due...
Journal Articles
Subject Area:
Oncology
Magnus Rizell, Fredrik Åberg, Mats Perman, Lars Ny, Liselotte Stén, Farida Hashimi, Joar Svanvik, Per Lindnér
Journal:
Case Reports in Oncology
Case Rep Oncol (2020) 13 (1): 478–484.
Published Online: 30 April 2020
... with a large CHC, which was radically resected, but the 53-year-old female patient subsequently developed pulmonary metastases. Histology demonstrated low-differentiated CHC without microsatellite instability. Treatment with sorafenib was started but was stopped due to angioedema. Under subsequent gemcitabine...
Journal Articles
Subject Area:
Oncology
Kazuhiro Katayama, Ryosuke Kiyota, Toshihiro Imai, Yutaro Abe, Tadatoshi Nawa, Hiroshi Wada, Kazuyoshi Ohkawa
Journal:
Case Reports in Oncology
Case Rep Oncol (2018) 11 (3): 711–720.
Published Online: 01 November 2018
...Kazuhiro Katayama; Ryosuke Kiyota; Toshihiro Imai; Yutaro Abe; Tadatoshi Nawa; Hiroshi Wada; Kazuyoshi Ohkawa Background and Objective: Sorafenib is recommended for treating advanced hepatocellular carcinoma. However, it is frequently discontinued because of adverse events, which greatly affects...
Journal Articles
Subject Area:
Oncology
Journal:
Case Reports in Oncology
Case Rep Oncol (2016) 9 (1): 134–137.
Published Online: 19 February 2016
.... In this case, multiple liver tumors existed in both lobes. Also this patient did not agree to receive surgical resection including liver transplantation. Chemotherapy with sorafenib at a dose of 400 mg/body twice a day was started. About 6 months later, CT findings revealed that these tumors were shrinking...
Journal Articles
Subject Area:
Oncology
Siraj M. Ali, Jessica Watson, Kai Wang, Jon H. Chung, Caitlin McMahon, Jeffrey S. Ross, Karel A. Dicke
Journal:
Case Reports in Oncology
Case Rep Oncol (2016) 9 (1): 112–118.
Published Online: 18 February 2016
... harboring MCL1 amplification, as identified by comprehensive genomic profiling in the course of clinical care. MCL1 is an antiapoptotic gene in the BCL2 family, and MCL1 amplification is common in TNBC (at least 20%). A personalized dose-reduced regimen centered on a combination of sorafenib and vorinostat...
Journal Articles
Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification
Subject Area:
Oncology
Journal:
Case Reports in Oncology
Case Rep Oncol (2015) 8 (1): 83–87.
Published Online: 11 February 2015
... treatment. We aim at reviewing our experience with sorafenib treatment of a patient with FLT3 mutation in refractory metastatic colorectal cancer. Methods: Treatment with sorafenib of a patient with metastatic colorectal cancer and FLT3 translocation who had previously been heavily treated. Results...
Journal Articles
Subject Area:
Oncology
Gema Bruixola, Ángel Segura, Javier Caballero, Ana Andrés, Encarnación Reche, Corina Escoín, Roberto Díaz-Beveridge
Journal:
Case Reports in Oncology
Case Rep Oncol (2014) 7 (2): 591–599.
Published Online: 20 August 2014
...: A 73-year-old lady had dedifferentiated papillary thyroid cancer with ongoing sorafenib. After 9 months on this treatment, she presented with dyspnea and heart failure. Differential diagnosis included infection, progression of disease and cardiotoxicity. After a comprehensive assessment...
Journal Articles
Subject Area:
Oncology
Journal:
Case Reports in Oncology
Case Rep Oncol (2014) 7 (1): 273–276.
Published Online: 25 April 2014
... awareness over the years. However, ILD induced by sorafenib was mentioned with lower frequency only in patients with hepatocellular and renal cell carcinoma living in Japan but not in patients with other carcinomas or living outside Japan, and it has been overlooked in clinical practice. In the present case...
Journal Articles
Subject Area:
Oncology
Hajime Mizukami, Tatehiro Kagawa, Yoshitaka Arase, Fumio Nakahara, Kota Tsuruya, Kazuya Anzai, Shunji Hirose, Koichi Shiraishi, Masako Shomura, Jun Koizumi, Kosuke Tobita, Tetsuya Mine
Journal:
Case Reports in Oncology
Case Rep Oncol (2012) 5 (2): 380–384.
Published Online: 24 July 2012
... sorafenib therapy at a dose of 800 mg/day, but discontinued it after 11 days due to grade 3 hand-foot skin reaction and rash. In spite of treatment termination, portal lymph node swelling disappeared and the serum des-γ-carboxy prothrombin and alpha-fetoprotein levels normalized. We considered that our...
Journal Articles
Subject Area:
Oncology
Dimitrios Zardavas, Alexander Meisel, Panagiotis Samaras, Alexander Knuth, Christoph Renner, Bernhard C. Pestalozzi, Frank Stenner-Liewen
Journal:
Case Reports in Oncology
Case Rep Oncol (2011) 4 (1): 16–18.
Published Online: 15 January 2011
.... Temsirolimus Chromophobe renal cell cancer Liver metastases Sunitinib Sorafenib Case Rep Oncol 2011;4:16 18 DOI: 10.1159/000323804 Published online: January 15, 2011 © 2011 S. Karger AG, Basel ISSN 1662 6575 www.karger.com/cro This is an Open Access article licensed under the terms of the Creative...
Journal Articles
Subject Area:
Oncology
Michele Basso, Maria Basso, Alessandro Iaculli, Maurizio Pompili, Laura Riccardi, Brunella Barbaro, Vittoria Rufini, Alessandra Cassano, Paola Castaldi, Carlo Barone
Journal:
Case Reports in Oncology
Case Rep Oncol (2010) 3 (3): 391–396.
Published Online: 06 November 2010
... bleak when the disease is complicated by portal vein tumor thrombosis (PVTT), since the increased portal pressure often causes serious gastrointestinal bleedings. Before the introduction of sorafenib (SOR), a tyrosine kinase inhibitor, no effective treatment was available for patients with advanced...
Journal Articles
Subject Area:
Oncology
Journal:
Case Reports in Oncology
Case Rep Oncol (2010) 3 (2): 298–303.
Published Online: 12 August 2010
...Takahide Nakazawa; Hisashi Hidaka; Akitaka Shibuya; Wasaburo Koizumi Background: Sorafenib is the first molecular-targeted agent that is effective for advanced hepatocellular carcinoma (HCC), with prolongation of survival. However, a complete response is very rare, and rapid regression of HCC after...